.
and damaged. This type of treatment in HER2-positive breast cancer, for example, leaves undiseased tissues undamaged by the therapy. The future of this ‘payload-delivery’ therapy (PDT) is that each type could be specifically designed to affect a target disorder or disease, and therefore only impact